2.693

1.62% +0.043

After Hours: 2.79 0.097 +3.60%

X.T.L. Biopharmaceuticals Ltd. ADR (XTLB)

Overview News Price History Discussions Forecast Stock Split

X.T.L. Biopharmaceuticals Ltd. ADR stock is currently priced at $2.693, with a 24-hour trading volume of 5,588. It has seen a +1.62% increased in the last 24 hours and a +9.03% rose in the past month. The chart indicates a potential bullish trend, as the stock is above the $2.67 pivot point. If it approaches the $2.73 resistance level, significant changes may occur.

Previous Close:

$2.65

Open:

$2.8

24h Volume:

5,588

Market Cap:

$14.67M

Revenue:

Net Income/Loss:

$-2.25M

P/E Ratio:

-5.6576

EPS:

-0.476

Net Cash Flow:

1W Performance:

+5.20%

1M Performance:

+9.03%

6M Performance:

+161.46%

1Y Performance:

+102.48%

1D Range:

$2.69

$2.84

52W Range:

$0.75

$4.9897

X.T.L. Biopharmaceuticals Ltd. ADR Stock (XTLB) Company Profile

Name

X.T.L. Biopharmaceuticals Ltd. ADR

Sector

Healthcare (1209)

Industry

Biotechnology (699)

Phone

972 3 611 6600

Address

5 Badner Street, Ramat Gan

Employee

Twitter

@xtlbio

Next Earnings Date

2024-05-24

Latest SEC Filings

XTLB's Discussions on Twitter

X.T.L. Biopharmaceuticals Ltd. ADR Stock (XTLB) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-08-15	Initiated	H.C. Wainwright	Buy

X.T.L. Biopharmaceuticals Ltd. ADR Stock (XTLB) Latest News

XTL Biopharmaceuticals Expands Portfolio Amidst Profitable Quarter - TipRanks.com - TipRanks

TipRanks

XTL Biopharmaceuticals Regains Nasdaq Compliance - TipRanks.com - TipRanks

TipRanks

Why Landos Biopharma Shares Are Trading Higher By Over 170%? Here Are Other Stocks Moving In Monday's Mid-Day Session

Benzinga

XTL Biopharmaceuticals Convenes Extraordinary General Meeting - TipRanks.com - TipRanks

TipRanks

XTL Biopharmaceuticals Convenes Extraordinary General Meeting - TipRanks.com - TipRanks

TipRanks

Dow Surges 350 Points; Fed Holds Rates Steady

Benzinga

X.T.L. Biopharmaceuticals Ltd. ADR Stock (XTLB) Financials Data

X.T.L. Biopharmaceuticals Ltd. ADR (XTLB) Net Income 2024

XTLB net income (TTM) was -$2.25 million for the quarter ending September 30, 2023, a -250.23% decrease year-over-year.

X.T.L. Biopharmaceuticals Ltd. ADR (XTLB) Earnings per Share 2024

XTLB earnings per share (TTM) was -$0.40 for the quarter ending September 30, 2023, a -279.37% decline year-over-year.

XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. The company's lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.